Introduction
For more than 20 years the French-American-British morphologic classification was the base for the diagnosis of myelodysplastic syndromes (MDS), a group of acquired clonal hematopoietic stem cell disorders with very heterogeneous outcomes and characterized by ineffective hematopoiesis, cytopenias, dysplastic morphologic features, and an increased risk of development of acute myeloid leukemia (AML) 1, 2 . In an attempt to improve its prognostic value, to incorporate other relevant morphological and biological prognostic characteristics, such as grade of myelodysplasia and cytogenetics, and to redefine the border between MDS and AML, an expert panel of Table 1 (modified from Vardiman JW et al. 5 ). Although the usefulness of the WHO classification was initially criticized 6, 7 , it has gained widespread acceptance 1, 8 . The 2001 WHO classification prognostic value is clearly superior than the FAB classification 9, 10 and has been incorporated into the recently defined WHO classification-based Prognostic Scoring System (WPSS) 11, 12 . However, 4 . Preference for inclusion in the study was given to cases diagnosed in more recent years and with good quality samples available. Table 2 summarizes the main characteristics of the patients.
Morphologic studies
Four smears from each included patient in the study were available for blind and independent microscopical review by four experienced cytologists from three centers. 
Results
The degree of concordance between observers for the different morphological characteristics is summarized in Table 3 .
Interobserver concordance in blast cells count
There was a strong agreement in the percentage of blast cells in BM considered as a continuous variable. The ICC for this parameter was 0.95 (95% confidence interval
[CI], 0.92-0.97; P < 0.001). When its degree of concordance was assessed stratifying the variable into 3 categories (<5%, 5 to 9%, and ≥ 10%), according to the thresholds used in WHO classification subtypes, the interobserver concordance was moderate (overall к, 0.57; P < 0.001). The degree of agreement was higher and significant when the BM blast percentage was less than 5% (к, 0.72; P < 0.001) or equal or greater to 10% (к, 0.65 P < 0.001), but it was lower for cases with an intermediate percentage of 
Interobserver concordance in ring sideroblasts count
The percentage of ring sideroblasts in BM showed a nearly perfect agreement between observers both analyzed as a continuous variable (ICC, 0.96; 95% CI, 0.93-0.98; P < 0.001) and with the 15% cut-off point used in WHO criteria (к, 0.82; P < 0.001). 
Reproducibility of WHO-defined MDS subtypes
The overall interobserver concordance for WHO-defined MDS subtypes showed a moderate overall agreement (к, 0.43; P < 0.001) ( Table 3 or with ≥ 10%. In those cases with ≥ 5% and < 10% blast cell count, the rate of concordance showed a moderate agreement. This implies that one patient could be classified as RCMD, RAEB-1 or RAEB-2 depending on the observer. We decided to evaluate the interobserver concordance for an additional cut-off point of 2% blasts in bone marrow for cases without excess of blasts because this threshold seems to portray prognostic relevance in the revised version of the IPSS 21 . The degree of agreement was adequate for cases with ≤ 2% blast cells but, again, it was not as good for cases between 2% and 5%. Discrepancies in the blast count in BM of patients with myeloid malignancies, including MDS, is partly due to the difficulty in distinguishing between granular blast cells and promyelocytes and the irregular distribution of blast cells in BM. In spite of a good correlation between the percentage of blasts determined by morphologic examination and percentage of CD34+ cells determined by flow cytometry is usually observed, blast enumeration by morphology is the gold-standard method 4, 22 .
The correct assignment of the percentage of blasts in PB is also crucial for a correct diagnosis and classification of patients 23 . In our study, we found a fair agreement in PB blast cell count. This result may be due to the low level of blast cells present in PB.
Interobserver discrepancies may best be resolved by increasing the number of cells in the differential counts.
The recognition of dysplastic signs has a crucial value not only for diagnosis and classification of MDS patients, but also a prognostic role in low risk MDS patients. In this regard, Pseudo-Pelger-Huët anomaly in neutrophils and micromegakaryocytes had been correlated with overall survival 17, 24 . Besides, several investigators support that cases with multilineage dysplasia have a less favorable prognosis than those with only dyserythropoietic dysplasia 10, [25] [26] . Thus, the WHO classification separated cases with refractory anemia in the previous FAB classification into two categories depending on the presence or absence of multilineage dysplastic features. This distinction has been criticized by some groups 6, 7 , because in clinical practice the assessment of the features of dysplasia is not always easy due to the lack of definition of objective parameters. Poor technical quality of the specimen could also be an obstacle to an accurate diagnosis of dysplasia. In our work we found a moderate but significant interobserver agreement for megakaryocytic and granulocytic dysplasia and a poor agreement for erythroid dysplasia. This is probably because features of dysgranulopoiesis (Pseudo-Pelger-Huët, hypogranularity) and dysmegakaryopoiesis (micromegakaryocytes, non-lobulated nuclei and multiple widely separated nuclei) are less subjective and more reproducible than features of erythroid dysplasia.
WHO classification includes a uniform threshold of 10% for dysplasia in each myeloid lineage; however, as discussed in the paper of Parmentier et al 27 , this level of dysplasia is highly questionable, it is particularly low in the megakaryocytic lineage where the number of cells analyzed is smaller than in the other series. We analyzed the interobserver concordance with a cut-off point of 40% dysplastic cells and we found that the agreement improved in the megakaryocytic and granulocytic lineage but not in the erythroid lineage. These results agree with those by Matsuda et al. 17 and
Germing et al. 28 who proposed to raise the threshold of dysmegakaryopoiesis from 10 to 40%.
The prognostic value of the WHO classification is already known 7,9,10,12 . Howe et al. We found a nearly moderate and significant concordance to define the 2008 WHO MDS subtypes (к, 0.43; P < 0.001). Most differences concerned the distinction of unilineage and multilineage dysplasia; consequently some patients were classified as RARS or RCMD depending on the recognition of dysplasia in one or more myeloid lineages. As previously described by Howe et al. 13 , we also had difficulties in assigning MDS subtype in those cases with borderline blast cell percentages. In fact, a substantial agreement was obtained only in cases with less than 2% or 5% or more than 10% of blast cells in BM. .
